

References

1. **Aaron, L., D. Saadoun, I. Calatroni, O. Launay, N. Memain, V. Vincent, G. Marchal, B. Dupont, O. Bouchaud, D. Valeyre, and O. Lortholary.** 2004. Tuberculosis in HIV-infected patients: A comprehensive review. *Clin. Microbiol. Infect.* **10**:388-398.
2. **Ainsa, J. A., C. Martin, and B. Gicquel.** 2001. Molecular approaches to tuberculosis. *Mol. Microbiol.* **42**:561-570.
3. **Al Dulayymi, J. R., M. S. Baird, H. H. Hussain, B. J. Alhourani, A. Y. Alhabashna, S. J. Coles, and M. B. Hursthouse.** 2000. The cycloaddition of cyclopropenes to enones. *Tetrahedron Lett.* **41**:4205-4208.
4. **Al Dulayymi, J. R., M. S. Baird, and K. Jones.** 2004. The absolute stereochemistry of grenadamide. *Tetrahedron* **60**:341-345.
5. **Al Dulayymi, J. R., M. S. Baird, H. Mohammed, E. Roberts, and W. Clegg.** 2006. The synthesis of one isomer of the α -methyl-*trans*-cyclopropane unit of mycolic acids. *Tetrahedron* **62**:4851-4862.
6. **Al Dulayymi, J. R., M. S. Baird, and E. Roberts.** 2003. The synthesis of a single enantiomer of a major α -mycolic acid of *Mycobacterium tuberculosis*. *Chem. Commun.*:228-229.
7. **Al Dulayymi, J. R., M. S. Baird, and E. Roberts.** 2005. The synthesis of a single enantiomer of a major α -mycolic acid of *Mycobacterium tuberculosis*. *Tetrahedron* **61**:11939-11951.
8. **Al Dulayymi, J. R., M. S. Baird, and E. Roberts.** 2000. The synthesis of single enantiomers of a meromycolic acid. *Tetrahedron Lett.* **41**:7107-7110.
9. **Alving, C. R., and G. M. J. Swartz.** 1991. Antibodies to cholesterol, cholesterol conjugates and liposomes: Implications for atherosclerosis and autoimmunity. *Crit. Rev. Immunol.* **10**:441-453.

10. **Alving, C. R., G. M. J. Swartz, and M. Wassef.** 1989. Naturally occurring autoantibodies to cholesterol in humans. *Biochem. Soc. Trans.* **629**:637-639.
11. **Anderson, R. J.** 1941. Structural peculiarities of acid-fast bacterial lipids. *Chem. Rev.* **29**:225-243.
12. **Antonucci, G., E. Girardi, M. Raviglione, and G. Ippolito.** 1995. Risk factors for tuberculosis in HIV-infected persons. A prospective study. *JAMA* **274**:143-148.
13. **Armstrong, J. A., and P. D. A. Hart.** 1971. Response of cultured macrophages to *Mycobacterium tuberculosis*, with observations on fusion of lysosomes with phagosomes. *J. Exp. Med.* **134**:713-740.
14. **Asselineau, J.** 1950. Sur la structure chimique des acides mycoliques isolés de *Mycobacterium tuberculosis* var. *hominis*; détermination de la position de l'hydroxyle. *C. R. Hebd. Seances. Acad. Sci.* **230**:1620-1622.
15. **Asselineau, J., and G. Lanéelle.** 1998. Mycobacterial lipids: A historical perspective. *Frontiers in Bioscience* **3**:e164-174.
16. **Asselineau, J., and E. Lederer.** 1950. Structure of the mycolic acids of mycobacteria. *Nature* **166**:782-783.
17. **Av-Gay, Y., and R. Sobouti.** 2000. Cholesterol is accumulated by mycobacteria but its degradation is limited to non-pathogenic fast-growing mycobacteria. *Can. J. Microbiol.* **46**:826-831.
18. **Baba, T., Y. Natsuhara, K. Kaneda, and I. Yano.** 1997. Granuloma formation activity and mycolic acid composition of mycobacterial cord factor. *Cell. Mol. Life Sciences* **53**:227-232.
19. **Barry, C. E., R. E. Lee, K. Mdluli, A. E. Sampson, B. G. Schroeder, R. A. Slayden, and Y. Yuan.** 1998. Mycolic acids: Structure, biosynthesis and physiological functions. *Prog. Lipid Res.* **37**:143-179.
20. **Bean, A. G., D. R. Roach, and H. Briscoe.** 1999. Structural deficiencies in granuloma formation in TNF gene targeted mice underlie the heightened susceptibility to aerosol

- Mycobacterium tuberculosis* infection, which is not compensated for by lymphotoxin. J. Immunol. **162**:3504-3511.
21. **Beckman, E. M., S. A. Porcelli, C. T. Morita, S. M. Behar, S. T. Furlong, and M. B. Brenner.** 1994. Recognition of a lipid antigen by CD1-restricted ab+ T cells. Nature **372**:691-694.
 22. **Bekierkunst, A., I. S. Levij, and E. Yarkoni.** 1968. Acute granulomatous response produced in mice by trehalose-6,6'-dimycolate. J. Bacteriol. **96**:958-961.
 23. **Bekierkunst, A., I. S. Levij, and E. Yarkoni.** 1971. Suppression of urethan-induced lung adenomas in mice treated with trehalose-6,6'-dimycolate (cord factor) and living BCG. Science **174**:1240-1242.
 24. **Benadie, Y.** 2007. Amphotericin B as a mycolic acid specific targeting agent in tuberculosis. MSc. Department of Biochemistry, University of Pretoria, Pretoria.
 25. **Besra, G. S., K. H. Khoo, M. R. McNeil, A. Dell, H. R. Morris, and P. J. Brennan.** 1995. A new interpretation of the structure of the mycolyl-arabinogalactan complex of *Mycobacterium tuberculosis* as revealed through characterization of oligoglycosyladitol fragments by fast-atom bombardment mass spectrometry and ¹H nuclear magnetic resonance spectroscopy. Biochemistry **34**:4257-4266.
 26. **Biro, A.** 2003. Serum anti-cholesterol antibodies in chronic hepatitis-C patients during IFN- α -2b treatment. Immunobiol. **207**:161-168.
 27. **Bloch, H.** 1950. Studies on the virulence of tubercle bacilli. Isolation and biological properties of a constituent of virulent organism. J. Exp. Med. **91**:197-217.
 28. **Brennan, P. J.** 1989. Structure of mycobacteria: recent developments in defining cell wall carbohydrates and proteins. Rev. Infect. Dis. **11**:S420-S430.
 29. **Brennan, P. J.** 2003. Structure, function and biogenesis of the cell wall of *Mycobacterium tuberculosis*. Tuberculosis **83**:91-97.
 30. **Brennan, P. J., and H. Nikaido.** 1995. The envelope of mycobacteria. Annu. Rev. Biochem. **64**:29-63.

31. **Buckle, P. E., R. J. Davies, T. Kinning, D. Yeung, P. R. Edwards, and D. Pollard-Knight.** 1993. The resonant mirror: A novel optical biosensor for direct sensing of biomolecular interactions. I: Principle of operation and associated instrumentation. *Biosens. Bioelectron.* **8**:347-355.
32. **Butler, W. R., and L. S. Guthertz.** 2001. Mycolic acids analysis by high-performance liquid chromatography for identification of *Mycobacterium* species. *Clin. Microbiol. Rev.* **14**:704-726.
33. **Chatterjee, D.** 1997. The mycobacterial cell wall: Structure, biosynthesis and sites of drug action. *Curr. Opin. Chem. Biol* **1**:579-588.
34. **Chatterjee, D., and K. H. Khoo.** 1998. Mycobacterial lipoarabinomannan: An extraordinary lipoheteroglycan with profound physiological effects. *Glycobiol.* **8**:113-120.
35. **Chatterjee, D., K. Lowell, B. Riviere, M. R. McNeil, and P. J. Brennan.** 1992. Lipoarabinomannan of *M. tuberculosis*. *J. Biol. Chem.* **267**:6234-6239.
36. **Collum, B. D., J. H. McDonald, and W. C. Still.** 1980. Synthesis of the polyether antibiotic monensin. 2. Preparation of intermediates. *J. Am. Chem. Soc.* **102**:2118-2120.
37. **Coxon, G. D., J. R. Al-Dulayymi, M. S. Baird, S. Knobl, E. Roberts, and D. E. Minnikin.** 2003. The synthesis of (11*R*,12*S*)-lactobacillic acid and its enantiomer. *Tetrahedron: Asymmetry* **14**:1221-1222.
38. **Coxon, G. D., J. R. Al Dulayymi, C. Morehouse, P. J. Brennan, G. S. Besra, M. S. Baird, and D. E. Minnikin.** 2004. Synthesis and properties of methyl 5-(1'*R*,2'*S*)-(2-octadecylcycloprop-1-yl)pentanoate and other ω -19 chiral cyclopropane fatty acids and esters related to mycobacterial mycolic acids. *Chemistry and Physics of Lipids* **127**:35-46.
39. **Coxon, G. D., S. Knobl, E. Roberts, M. S. Baird, J. R. Al Dulayymi, G. S. Besra, P. J. Brennan, and D. E. Minnikin.** 1999. The synthesis of both enantiomers of lactobacillic acid and mycolic acid analogues. *Tetrahedron Lett.* **40**:6689-6692.

40. **Crowe, L. M., B. J. Spargo, T. Ionedá, B. L. Beaman, and J. H. Crowe.** 1994. Interaction of cord factor (trehalose-6,6'-dimycolate) with phospholipids. *Biochim. Biophys. Acta.* **1194**:53-60.
41. **Cush, R., J. M. Cronin, and W. J. Stewart.** 1993. The resonant mirror: A novel optical biosensor for direct sensing of biomolecular interactions Part I: Principle of operation and associated instrumentation. *Biosens. Bioelectron.* **8**:347-354.
42. **Daffé, M., and P. Draper.** 1998. The envelope layers of mycobacteria with reference to their pathogenicity. *Adv. Microb. Physiol.* **39**:131-203.
43. **Daffé, M., and D. Lanéelle.** 1988. Distribution of phthiocerol diester, phenolic mycosides and related compounds in mycobacteria. *J. Gen. Microbiol.* **134**:2049-2055.
44. **Daffé, M., and M. A. Lanéelle.** 1991. Structure and stereochemistry of mycolic acids of *Mycobacterium tuberculosis* and *Mycobacterium ulcerans*. *Res. Microbiol.* **142**:397-403.
45. **Daffé, M., M. A. Lanéelle, G. Puzo, and C. Asselineau.** 1981. Acide mycolique epoxidique: un nouveau type d'acide. *Tetrahedron Lett.* **22**:4515-4516.
46. **De Chastellier, C., T. Lang, and L. Thilo.** 1995. Phagocytic processing of the macrophage endoparasite, *Mycobacterium avium*, in comparison to phagosomes which contain *Bacillus subtilis* or latex beads. *Eur. J. Cell. Biol.* **68**:167-182.
47. **De Chastellier, C., and L. Thilo.** 1997. Phagosome maturation and fusion with lysosomes in relation to surface property and size of the phagocytic particle. *Eur. J. Cell. Biol.* **74**:49-62.
48. **Dobson, G., D. E. Minnikin, S. M. Minnikin, J. H. Parlett, and M. Goodfellow.** 1985. Systematic analysis of complex mycobacterial lipids, p. 237-265. *In* M. Goodfellow and D. E. Minnikin (ed.), *Chemical methods in bacterial systematics*. The society for applied bacteriology.
49. **Draper, P.** 1998. The outer parts of the mycobacterial envelope as permeability barriers. *Frontiers in Bioscience* **3**:1253-1261.

50. **Dubnau, E., J. Chan, C. Raynaud, V. P. Mohan, M. A. Lanéelle, K. Yu, A. Quémard, I. Smith, and M. Daffé.** 2000. Oxygenated mycolic acids are necessary for virulence of *Mycobacterium tuberculosis* in mice. *Mol. Microbiol.* **36**:630-637.
51. **Dubnau, E., M. A. Lanéelle, S. Soares, A. Benichou, T. Vaz, D. Promé, J. C. Promé, M. Daffé, and A. Quémard.** 1997. *Mycobacterium bovis* BCG genes involved in the biosynthesis of cyclopropyl keto- and hydroxy-mycolic acids. *Mol. Microbiol.* **23**:313-322.
52. **Durand, E., M. Gillois, J. F. Tocanne, and G. Lanéelle.** 1979. Property and activity of mycoloyl esters of methyl glucoside and trehalose. Effect on mitochondrial oxidative phosphorylation related to organization of suspensions and to acyl-chain structures. *Eur. J. Biochem.* **94**:109-118.
53. **Durand, E., M. Welby, G. Lanéelle, and J. F. Tocanne.** 1979. Phase behaviour of cord factor and related bacterial glycolipid toxins. A monolayer study. *Eur. J. Biochem.* **93**:103-112.
54. **Ehlers, S., M. E. A. Milke, and H. Hahn.** 1994. Progress in TB research: Robert Koch's dilemma revisited. *Immunol. Today* **15**:1-4.
55. **Ellner, J. J.** 1997. Review: The immune response in human tuberculosis: implications for tuberculosis control. *J. Infect. Dis.* **176**:1351-1359.
56. **Fenton, M. J., and M. W. Vermeulen.** 1996. Immunopathology of tuberculosis: Roles of macrophages and monocytes. *Infect. Immun.* **64**:683-690.
57. **Ferrari, G., H. Langen, N. M., and J. Pieters.** 1999. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. *Cell* **97**:435-437.
58. **Filling, C., K. D. Berndt, J. Benach, S. Knapp, T. Prozorovski, E. Nordling, R. Ladenstein, H. Jornvall, and U. Oppermann.** 2002. Critical residues for structure and catalysis in short-chain dehydrogenases/reductases. *J. Biol. Chem.* **277**:25677-25684.
59. **Flynn, J. L., and J. Chan.** 2001. Tuberculosis: Latency and reactivation. *Infect. Immun.* **69**:4195-4201.

60. **Flynn, J. L., and J. D. Ernst.** 2000. Immune responses in tuberculosis. *Curr. Opin. Immunol.* **12**:432-436.
61. **Flynn, J. L., M. M. Goldstein, and J. Chan.** 1995. Tumour necrosis factor-alpha is required in the protective immune response against *Mycobacterium tuberculosis* in mice. *Immunity* **2**:561-572.
62. **Frieden, T. R., T. R. Sterling, S. S. Munsiff, C. J. Watt, and C. Dye.** 2003. Tuberculosis. *Lancet* **362**:887-899.
63. **Fujita, Y., T. Doi, R. Maekura, M. Ito, and I. Yano.** 2006. Differences in serological responses to specific glycopeptidolipid-core and common lipid antigens in patients with pulmonary disease due to *Mycobacterium tuberculosis* and *Mycobacterium avium* complex. *J. Med. Microbiol.* **55**:189-199.
64. **Fujita, Y., T. Doi, K. Sato, and I. Yano.** 2005. Diverse humoral immune responses and changes in IgG antibody levels against mycobacterial lipid antigens in active tuberculosis. *Microbiol.* **151**:2065-2074.
65. **Fujiwara, N., J. Pan, K. Enomoto, Y. Terano, T. Honda, and I. Yano.** 1999. Production and partial characterization of anti-cord factor (trehalose-6,6'-dimycolate) IgG antibody in rabbits recognizing mycolic acid subclasses of *Mycobacterium tuberculosis* or *Mycobacterium avium*. *FEMS Immunol. Med. Microbiol.* **24**:141-149.
66. **Gatfield, J., and J. Pieters.** 2000. Essential role for cholesterol in entry of mycobacteria into macrophages. *Science* **288**:1647-1650.
67. **Goodrum, M. A., D. G. R. Siko, T. Niehues, D. Eichelbauer, and J. A. Verschoor.** 2001. Mycolic acids from *Mycobacterium tuberculosis*: Purification by countercurrent distribution and T-cell stimulation. *Microbios* **106**:55-67.
68. **Grandjean, D., P. Pale, and J. Chuche.** 1991. Enzymatic hydrolysis of cyclopropanes. Total synthesis of optically pure dictyopterens a and c. *Tetrahedron* **47**:1215-1230.
69. **Grange, J. M.** 1988. *Mycobacteria and human disease*. Edward Arnold Ltd, London.
70. **Grant, E. P., E. M. Beckman, S. M. Behar, M. Degano, D. Frederique, G. S. Besra, I. A. Wilson, S. A. Porcelli, S. T. Furlong, and M. B. Brenner.** 2002. Fine specificity

of TCR complementarity-determining region residues and lipid antigen hydrophilic moieties in the recognition of a CD1-lipid complex. *J. Immunol.* **168**:3933-3940.

71. **Gray, G. R., M. Y. H. Wong, and S. J. Danielson.** 1982. The major mycolic acids of *Mycobacterium smegmatis*. *Prog. Lip. Res.* **21**:91-107.
72. **Grzybowski, S., and E. A. Allen.** 1964. The challenge of tuberculosis in decline. A study based on the epidemiology of tuberculosis in Ontario, Canada. *Am. Rev. Resp. Dis.* **90**:707-720.
73. **Hart, P. D., J. A. Armstrong, C. A. Brown, and P. Draper.** 1972. Ultrastructural study of the behavior of macrophages toward parasitic mycobacteria. *Infect. Immun.* **5**:803-807.
74. **Hasan, Z.** 1997. Isolation and characterization of the mycobacterial phagosome: segregation from the endosomal/lysosomal pathway. *Mol. Microbiol.* **24**:545-553.
75. **Hasegawa, T., S. Amino, S. Kitamura, L. Matsumoto, S. I. Katada, and J. Nishijo.** 2003. Study of the molecular conformation of α - and keto-mycolic acid monolayers by Langmuir-Blodgett technique and fourier transform infrared reflection-absorption spectroscopy. *Langmuir* **19**:105-109.
76. **Hasegawa, T., and R. M. Leblanc.** 2003. Aggregation properties of mycolic acids molecules in monolayers films: A comparative study of compounds from various acid-fast bacterial species. *Biochim. Biophys. Acta.* **1617**:89-95.
77. **Hashimoto, N., T. Aoyama, and S. Takayuki.** 1981. New methods and reagents in organic synthesis. 14. A simple efficient preparation of methyl esters with trimethylsilyl diazomethane (TMSCHN₂) and its applications to gas chromatography analysis of fatty acids. *Chem. Pharm. Bull.* **29**:1475-1478.
78. **He, H., S. Oka, Y. Han, M. Yamamura, E. Kusunose, M. Kusunose, and I. Yano.** 1991. Rapid serodiagnosis of human mycobacteriosis by ELISA using cord factor (trehalose-6,6'-dimycolate) purified from *Mycobacterium tuberculosis* as antigen. *FEMS Microbiol. Immunol.* **76**:201-204.

79. **Horvath, A.** 2001. High level of anticholesterol antibodies (ACHA) in HIV patients. Normalization of serum ACHA concentration after introduction of HAART. *Immunobiol.* **203**:756-768.
80. **Huang, H. C., J. K. Rehmann, and G. R. Gray.** 1982. Total synthesis of naturally occurring mycolic acids. (*E*)- and (*Z*)-threo-2-docosyl-3-hydroxytetracont-21-enoate. *J. Org. Chem.* **47**:4018-4023.
81. **Kaneda, K., S. Imiaiszumi, T. Baba, M. Tsukamura, and I. Yano.** 1988. Structure and molecular species composition of three homologous series of α -mycolic acids from *Mycobacterium* spp. *J. Gen. Microbiol.* **134**:2213-2229.
82. **Kato, M.** 1972. Antibody formation to trehalose 6,6'-dimycolate (cord factor) of *Mycobacterium tuberculosis*. *Infect. Immun.* **5**:203-212.
83. **Kaufmann, S. H.** 2001. How can immunology contribute to the control of tuberculosis? *Nat. Rev. Immunol.* **1**:20-30.
84. **Kaul, D.** 2001. Molecular link between cholesterol, cytokines and atherosclerosis. *Mol. Cell. Biochem.* **219**:65-71.
85. **Kaul, D., P. K. Anand, and I. Verma.** 2004. Cholesterol-sensor initiates *M. tuberculosis* entry into human macrophages. *Mol. Cell. Biochem.* **258**:219-222.
86. **Kaul, D., and M. Kaur.** 1998. Receptor-C_k controls the expression of Bcl-2 and cyclin d genes. *Leuk. Res.* **22**:671-675.
87. **Kawamura, M., N. Sueshige, K. Imayoshi, I. Yano, R. Maekura, and H. Kohno.** 1997. Enzyme immunoassay to detect antituberculous glycolipid antigen (anti-TBGL antigen) antibodies in serum for diagnosis of tuberculosis. *J. Clin. Lab. Anal.*:140-145.
88. **Keet, D. F., N. P. Kriek, M. L. Penrith, A. Michel, and H. Huchzermeyer.** 1996. Tuberculosis in buffaloes (*Syncerus caffer*) in the Kruger National Park: spread of the disease to other species. *Onderstepoort J. Vet. Res.* **63**:239-244.
89. **Korf, J. E., A. C. Stoltz, J. A. Verschoor, P. de Baetselier, and J. Grooten.** 2005. The *Mycobacterium tuberculosis* cell wall component mycolic acid elicits pathogen-associated host innate immune responses. *Eur. J. Immunol.* **35**:890-900.

90. **Koza, G., and M. S. Baird.** 2007. The first synthesis of a single enantiomer of a ketomycolic acid. *Tetrahedron Letters* **48**:2165-2169.
91. **Lacave, C., M. A. Lanéelle, M. Daffé, H. Montrozier, M. P. Rols, and C. Asselineau.** 1987. Structural and metabolic study of the mycolic acids of *Mycobacterium fortuitum*. *Eur. J. Biochem.* **163**:369-378.
92. **Lanéelle, M. A., and G. Lanéelle.** 1970. Structure d'acides mycoliques et d'un intermédiaire dans la biosynthèse d'acides dicarboxyliques. *Eur. J. Biochem.* **12**:296-300.
93. **Laval, F., M. A. Lanéelle, C. Deon, B. Monsarrat, and M. Daffé.** 2001. Accurate molecular mass determination of mycolic acids by MALDI-TOF mass spectrometry. *Anal. Chem.* **73**:4537-4544.
94. **Long, R., and M. Gardam.** 2003. Tumour necrosis factor- α inhibitors and the reactivation of latent tuberculosis infection. *CMAJ* **168**:1153-1156.
95. **Lopez-Marin, L. M., E. Segura, C. Hermida-Escobedo, A. Lemassu, and M. C. Salinas-Carmona.** 2003. 6,6'-Dimycoloyl trehalose from rapidly growing *Mycobacterium*: An alternative antigen for tuberculosis serodiagnosis. *Immunol. Med. Microbiol.* **36**:47-54.
96. **Luquin, M., J. Roussel, F. Lopez-Calahorra, G. Lanéelle, V. Ausina, and M. A. Lanéelle.** 1990. A novel mycolic acid in a *Mycobacterium* sp. from the environment. *Eur. J. Biochem.* **192**:753-759.
97. **Maekura, R., M. Nakagawa, Y. Nakamura, T. Hiraga, Y. Yamamura, M. Ito, E. Ueda, S. Yano, H. He, S. Oka, K. Kashima, and I. Yano.** 1993. Clinical evaluation of rapid serodiagnosis of pulmonary tuberculosis by ELISA with cord factor (trehalose 6,6'-dimycolate) as antigen purified from *Mycobacterium tuberculosis*. *Am. Rev. Respir. Dis.* **148**:997-1001.
98. **McNeil, M.** 1996. Targeted preclinical drug development for *Mycobacterium avium* complex: a biochemical approach, p. 263-283. *In* J. A. Korvick and C. A. Benson (ed.), *Mycobacterium avium* complex infection. Marcel Dekker Inc, New York.

99. **Michel, A., R. G. Bengis, D. F. Keet, M. Hofmeyr, L. M. Klerk, P. C. Cross, A. E. Jolles, D. Cooper, I. J. Whyte, P. Buss, and J. Godfroid.** 2006. Wildlife tuberculosis in South African conservation areas: implications and challenges. *Veterinary Microbiology* **12**:91-100.
100. **Minnikin, D. E.** 1982. Lipids: Complex lipids, their chemistry, biosynthesis and roles., p. 95-184. *In* C. Ratledge and J. Stanford (ed.), *The biology of the mycobacterium: Physiology, identification and classification*. Academic Press, Inc, San Diego.
101. **Minnikin, D. E., and M. Goodfellow.** 1980. Lipid composition in the classification and identification of acid-fast bacteria. *Soc. Appl. Bacteriol. Symp. Ser.* **8**:189-256.
102. **Minnikin, D. E., L. Kremer, L. G. Dover, and G. S. Besra.** 2002. The methyl-branched fortifications of *Mycobacterium tuberculosis*. *Chem. Biol.* **9**:545-553.
103. **Minnikin, D. E., S. M. Minnikin, and M. Goodfellow.** 1982. The oxygenated mycolic acids of *Mycobacterium tuberculosis*, *M. farcinogenes* and *M. senegalese*. *Biochim. Biophys. Acta.* **712**:616-620.
104. **Minnikin, D. E., S. M. Minnikin, J. H. Parlett, M. Goodfellow, and M. Magnusson.** 1984. Mycolic acid patterns of some species of *Mycobacterium*. *Arch. Microbiol.* **139**:225-231.
105. **Minnikin, D. E., and N. Polgar.** 1967. The methoxymycolic and ketomycolic acids from human tubercle bacilli. *Chem. Comm.:*1172-1174.
106. **Minnikin, D. E., and N. Polgar.** 1967. The mycolic acids from human and avian tubercle bacilli. *Chem. Comm.:*916-918.
107. **Mohan, V. P., C. A. Scanga, K. Yu, H. M. Scott, K. E. Tanaka, E. Tsang, M. C. Tsai, J. L. Flynn, and J. Chan.** 2001. Effects of tumour necrosis factor-alpha on host immune response in chronic persistent tuberculosis: Possible role for limiting pathology. *Infect. Immun.* **69**:1847-1855.
108. **Morimoto, Y., S. Kitao, Y. Okita, and T. Shoji.** 2003. Total synthesis and assignment of the double-bond position and absolute configuration of (-)-pyrinodemin A. *Org. Lett.* **5**:2611-2614.

109. **Nilsson, K., and C. Ullenius.** 1994. Stereoselectivity in the 1,4-addition reaction of organocopper reagents to ethyl 3-[(S)-2,2-dimethyl-1,3-dioxolan-4-yl]propenoate. *Tetrahedron* **50**:13173-13180.
110. **Noll, H., and H. Bloch.** 1955. Studies on the chemistry of the cord factor of *Mycobacterium tuberculosis*. *J Biol Chem* **214**:251-265.
111. **Nunn, P., B. Williams, K. Floyd, C. Dye, G. Elzinga, and M. Raviglione.** 2005. Tuberculosis control in the era of HIV. *Nat. Rev. Immunol.* **5**:819-826.
112. **Pan, J., N. Fujiwara, S. Oka, R. Maikura, T. Ogura, and I. Yano.** 1999. Anti-cord factor (trehalose-6,6'-dimycolate) IgG antibody in tuberculosis patients recognizes mycolic acid subclasses. *Microbiol. Immunol.* **43**:863-869.
113. **Peloquin, C. A., and S. E. Berning.** 1994. Infection caused by *Mycobacterium tuberculosis*. *Annals of Pharmacotherapy* **28**:72-84.
114. **Porcelli, S., C. T. Morita, and M. B. Brenner.** 1992. CD1b restricts the response of human CD4⁺8⁻ T lymphocytes to a microbial antigen.
115. **Pretorius, A.** 1999. Humoral and cellular immunogenicity of mycobacterial mycolic acids in tuberculosis. MSc. Department of Biochemistry, University of Pretoria, Pretoria.
116. **Qureshi, N., K. Takayama, H. C. Jordi, and H. K. Schones.** 1978. Characterization of the purified components of a new homologous series of α -mycolic acids from *Mycobacterium tuberculosis* H37Ra. *J. Biol. Chem.* **253**:5411-5417.
117. **Raja, A.** 2004. Immunology of tuberculosis. *Indian J. Med. Res.* **120**:213-232.
118. **Retzinger, G. S., S. C. Meredith, K. Takayama, R. L. Hunter, and F. J. Kezdy.** 1981. The role of surface in the biological activities of trehalose 6,6'-dimycolate. Surface properties and development of a model system. *J. Biol. Chem.* **256**:8208-8216.
119. **Ribi, E., D. L. Granger, K. C. Milner, K. Yamamoto, S. M. Strain, and R. Parker.** 1982. Induction of resistance to tuberculosis in mice with defined components of mycobacteria and with some unrelated materials. *Immunol.* **46**:297-305.

120. **Rodwell, T. C., N. P. Kriek, R. G. Bengis, I. J. Whyte, P. C. Viljoen, V. de Vos, and W. M. Boyce.** 2001. Prevalence of bovine tuberculosis in African buffalo at Kruger National Park. *J. Wildlife Dis.* **37**:258-264.
121. **Rozwarski, D. A., C. Vilcheze, M. Sugantino, R. Bittman, and J. C. Sacchettini.** 1999. Crystal structure of the *Mycobacterium tuberculosis* enoyl-ACP reductase, InhA, in complex with NAD⁺ and a C16 fatty acyl substrate. *J. Biol. Chem.* **274**:15582-15589.
122. **Russell, D. G.** 2001. *Mycobacterium tuberculosis*: here today, and here tomorrow. *Nat. Rev. Mol. Cell Biol.* **2**:569-577.
123. **Ryll, R., Y. Kumazawa, and I. Yano.** 2001. Immunological properties of trehalose dimycolate (cord factor) and other mycolic acid-containing glycolipids. *Microbiol. Immunol.* **45**:801-811.
124. **Ryosuke, M., T. Ueki, H. Katakai, K. Takao, and K. Tadano.** 2001. Synthetic study of macquarimicins: Highly stereoselective construction of the AB-ring system. *Org. Lett.* **3**:3029-3032.
125. **Saita, N., A. Fujimura, I. Yano, and K. K. Soejima.** 2000. Trehalose-6,6'-dimycolate (cord factor) of *Mycobacterium tuberculosis* induces corneal angiogenesis in rats. *Infect. Immun.* **68**:5991-5997.
126. **Sakaguchi, I., N. Ikeda, M. Nakayama, Y. Kato, I. Yano, and K. Kaneda.** 2000. Trehalose-6,6'-dimycolate (cord factor) enhances neovascularization through vascular endothelial growth factor production by neutrophils and macrophages. *Infect. Immun.* **68**:2043-2052.
127. **Schleicher, G. K., C. Feldman, Y. Vermaak, and J. A. Verschoor.** 2002. Prevalence of anti-mycolic acid antibodies in patients with pulmonary tuberculosis co-infected with HIV. *Clin. Chem. Lab. Med.* **40**:882-887.
128. **Schluger, N. W., and W. N. Rom.** 1997. The host immune response to tuberculosis. *Am. J. Resp. Crit. Care Med.* **157**:679-691.
129. **Sechi, L. A., M. Mura, F. Tanda, A. Lissia, A. Solinas, G. Fadda, and S. Zanetti.** 2001. Identification of *Mycobacterium avium* subsp. *paratuberculosis* in biopsy

specimens from patients with Crohn's disease identified by *in situ* hybridization.

39:4514-4517.

130. **Sekanka, G., M. S. Baird, D. E. Minnikin, and J. Grooten.** 2007. Mycolic acids for the control of tuberculosis. *Expert Opin. Ther. Patents* **17:315-331.**
131. **Selwyn, P. A., D. Hartel, V. A. Lewis, E. E. Schoenbaum, S. H. Vermund, R. S. Klein, A. T. Walker, and G. H. Freidland.** 1989. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. *N. Engl. J. Med.* **320:545-550.**
132. **Seyferth, D., H. Menzel, A. W. Dow, and T. C. Flood.** 1972. Trimethylsilyl-substituted diazoalkanes. I Trimethylsilyl diazomethane. *J. Organomet. Chem.* **44:279-290.**
133. **Sieling, P. A., D. Chatterjee, S. A. Porcelli, T. L. Prigozy, R. J. Massaccaro, T. Soriano, B. R. Bloom, M. B. Brenner, M. Kronenberg, P. J. Brennan, and R. L. Modlin.** 1995. CH1-restricted T cell recognition of microbial lipoglycan antigens. *Science* **269:227-230.**
134. **Siko, D. G. R.** 2002. Mycobacterial mycolic acids as immunoregulatory lipid antigens in the resistance to tuberculosis. PhD. Department of Biochemistry, University of Pretoria, Pretoria.
135. **Sodhi, A., J. Gong, C. Silva, D. Qian, and P. F. Barnes.** 1997. Clinical correlates of interferon-gamma production in patients with tuberculosis. *Clin. Infect. Dis.* **25:617-620.**
136. **Spargo, B. J., L. M. Crowe, T. Ionedá, B. L. Beaman, and J. H. Crowe.** 1991. Cord factor (trehalose-6,6'-dimycolate) inhibits fusion between phospholipid vesicles. *PNAS* **88:737-740.**
137. **Spencer, H.** 1985. *Pathology of the lung*, 4th ed, vol. 1. Pergamon Press, Oxford.
138. **Stead, W. W., and J. P. Lofgren.** 1983. Does the risk of tuberculosis increase in old age? *J. Infect. Dis.* **147:951-955.**
139. **Steck, P. A., B. A. Schwartz, M. S. Rosendahl, and G. R. Gray.** 1978. Mycolic acids: A reinvestigation. *J. Biol. Chem.* **253:5625-5629.**

140. **Stodola, F. H., A. Lesuk, and R. J. Anderson.** 1938. The chemistry of the lipids of tubercle bacilli. LIV The isolation and properties of mycolic acid. *J. Biol. Chem.* **126**:505-513.
141. **Stybło, K.** 1980. Recent advances in epidemiological research in tuberculosis. *Adv. Tuberc. Res.* **20**:1-63.
142. **Thanyani, T. S.** 2003. A novel application of affinity biosensor technology to detect antibodies to mycolic acid in tuberculosis patients. MSc. Department of Biochemistry, University of Pretoria, Pretoria.
143. **Van Deventer, S. J. H.** 2001. Transmembrane TNF- α , induction of apoptosis and the efficacy of TNF-targeting therapies in Crohn's disease. *Gastroenterology* **121**:1242-1246.
144. **van Regenmortel, M.** 1999. The antigenicity of tobacco mosaic virus. *Philosophical Transactions: Biological Sciences* **354**:559-568.
145. **Villeneuve, M., M. Kawai, H. Kanashima, M. Watanabe, D. E. Minnikin, and H. Nakahara.** 2005. Temperature dependence of the Langmuir monolayer packing of mycolic acids from *Mycobacterium tuberculosis*. *Biochim. Biophys. Acta* **1715**:71-80.
146. **Villeneuve, M., M. Kawai, M. Watanabe, Y. Aoyagi, Y. Hitotsuyanagi, K. Takeya, H. Gouda, S. Hirono, D. E. Minnikin, and H. Nakahara.** 2007. Conformational behavior of oxygenated mycobacterial mycolic acids from *Mycobacterium bovis* BCG. *Biochim. Biophys. Acta* **1768**:1717-1726.
147. **Vrey, P. J.** 2004. Lipid ligand-protein receptor interactions characterised by a resonant mirror biosensor. MSc. Department of Biochemistry, University of Pretoria, Pretoria.
148. **Wang, L., R. A. Slayden, C. E. Barry, and J. Liu.** 2000. Cell wall structure of a mutant of *Mycobacterium smegmatis* defective in the biosynthesis of mycolic acids. *J. Biol. Chem.* **275**:7224-7229.
149. **Watanabe, M., Y. Aoyagi, H. Mitome, T. Fujita, H. Naoki, M. Ridell, and D. E. Minnikin.** 2002. Location of functional groups in mycobacterial meromycolate chains; the recognition of new structural principles in mycolic acids. *Microbiol.* **148**:1881-1902.

150. **Watanabe, M., Y. Aoyagi, M. Ridell, and D. E. Minnikin.** 2001. Separation and characterization of individual mycolic acids in representative mycobacteria. *Microbiol.* **147**:1825-1837.
151. **Watanabe, M., A. Ohata, S. Sasaki, and D. E. Minnikin.** 1999. Structure of a new glycolipid from *Mycobacterium avium-Mycobacterium intracellulare* complex. *J. Bacteriol.* **181**:2293-2297.
152. **WHO.** 2005. Fact sheet No 104: Tuberculosis.
153. **WHO.** 2001. Fact sheet No 199: Buruli ulcer.
154. **WHO.** 2006. Global Tuberculosis control. Surveillance, planning, financing. World Health Organization.
155. **WHO.** 2004. Status rapport: Leprosy elimination project.
156. **Williams, B. G., and C. Dye.** 2003. Anti-retroviral drugs for tuberculosis control in the era of HIV/AIDS. *Science* **301**:1535-1537.
157. **Yano, I., S. Oka, Y. Ueno, Y. Natsuhara, J. Yoshinaga, and Y. Kato.** 1990. Reagent for detecting antibody corresponding to acid-fast bacterium antigen and application thereof. Japan patent PCT/JP89/01341.
158. **Yuan, Y., D. Mead, B. G. Schroeder, Y. Zhu, and C. E. Barry.** 1998. The biosynthesis of mycolic acids in *Mycobacterium tuberculosis*. *J. Biol. Chem.* **273**:21282-21290.
159. **Zimmerli, S., S. Edwards, and J. D. Ernst.** 1996. Selective receptor blockade during phagocytosis does not alter the survival and growth of *Mycobacterium tuberculosis* in human macrophages. *Am. J. Respir. Cell Mol. Biol.* **15**:760-770.